The current STATe of biomarkers to predict the response to anti-angiogenic therapies

Cancer Biology and Therapy

Volumn 7, Issue 12, 2008, Pages 2004-2006

  Tran, Phuoc T ^a   Felsher, Dean W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Anti angiogenic; Signaling; Src; STAT3; Tissue biomarker; VEGFR2

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; SEMAXANIB; SORAFENIB; STAT3 PROTEIN; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC THERAPY; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; DRUG RESPONSE; HUMAN; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; NOTE; RECEPTOR BINDING; SOLID TUMOR; TREATMENT OUTCOME;

EID: 58149114607     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.12.7191     Document Type: Note

References (24)

1. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358:2039-49.
2. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004; 64:8249-55.
3. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature reviews 2008; 8:592-603.
4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50.
5. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666-76.
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90.
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-34.
9. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24.
10. Gillick MR. Molecular medicine, the Medicare drug benefit, and the need for cost control. J Am Geriatr Soc 2006; 54:1442-6.
11. DePrimo SE, Wong LM, Khatry DB, Nicholas SL, Manning WC, Smolich BD, et al. Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. BMC Cancer 2003; 3:3.
12. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005; 16:558-65.
13. Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, et al. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 2006; 24:1449-53.
14. Provenzale JM. Imaging of angiogenesis: clinical techniques and novel imaging methods. AJR Am J Roentgenol 2007; 188:11-23.
15. Chen S-H, Murphy DA, Lassoued W, Thurston G, Feldman MD, Lee WMF. Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer biology & therapy 2008; 7.
16. Takahashi T, Yamaguchi S, Chida K, Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLCgamma and DNA synthesis in vascular endothelial cells. The EMBO journal 2001; 20:2768-78.
17. Holmqvist K, Cross MJ, Rolny C, Hagerkvist R, Rahimi N, Matsumoto T, et al. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. The Journal of biological chemistry 2004; 279:22267-75.
18. Yu H, Jove R. The STATs of cancer - new molecular targets come of age. Nature reviews 2004; 4:97-105.
19. Yahata Y, Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, Hanakawa Y, et al. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. The Journal of biological chemistry 2003; 278:40026-31.
20. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005; 16:601-7.
21. Bartoli M, Platt D, Lemtalsi T, Gu X, Brooks SE, Marrero MB, et al. VEGF differentially activates STAT3 in microvascular endothelial cells. Faseb J 2003; 17:1562-4.
22. Bartoli M, Gu X, Tsai NT, Venema RC, Brooks SE, Marrero MB, et al. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. The Journal of biological chemistry 2000; 275:33189-92.
23. Helft PR, Daugherty CK. Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation. J Clin Oncol 2006; 24:4793-5.
24. Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. The Journal of biological chemistry 1997; 272:15442-51.